Strategy’s Bitcoin Stockpile Nears BlackRock’s ETF Holdings After $1 Billion BTC Buy

In brief Strategy notched its largest Bitcoin purchase in nearly a month, expanding its holdings with proceeds that purely came from its flagship preferred share. The Bitcoin-buying firm is within striking distance of surpassing BlackRock’s spot Bitcoin ETF. Michael Saylor said that Strategy could cover its dividend obligation indefinitely if Bitcoin’s price appreciated 2% each…

Read More

GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

Animals and housing conditions Experiments were performed in accordance with the Animal Protection Law of the European Union after permission by the Governments of Upper Bavaria, Germany, or Copenhagen, Denmark, or by the Institutional Animal Care and Use Committees of the Universities of Texas Southwestern, Michigan, Duke or Yale, USA. Mice were double- or single-housed…

Read More

Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup

Sample acquisition and ethics approval The University of Pennsylvania institutional review board (IRB) approved the collection of human kidney tissue for this study. Left-over kidney samples were irreversibly de-identified, and no personal identifiers were gathered. Therefore, they were exempt from IRB review (category 4). We engaged an external, honest broker who was responsible for clinical…

Read More

Runners v robots at China half marathon

Robots competed in a half marathon race in Beijing on Sunday, with the fastest machine leaving its human rivals for dust. The winning robot, Lightning, was developed by Chinese smartphone maker Honor and finished the race in 50 minutes and 26 seconds, according to race organisers. Uganda’s Jacob Kiplimo holds the men’s half marathon world…

Read More

Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer

Lap-NET1 clinical trial Study design and participants Lap-NET1 is a multicentric, prospective, single-arm phase 1b trial. This study included a safety lead-in phase to confirm the recommended dose of NP137 in combination with mFOLFIRINOX (ClinicalTrials.gov identifier: NCT05546853). Patients were enrolled and treated between March 2023 and June 2024 at nine sites in France. Eligible patients…

Read More